Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[1] Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi
Zaja, Francesco
Salvi, Flavia
Franceschetti, Silvia
Gaidano, Gianluca
Ladetto, Marco
Zanni, Manuela
Pica, Gian Matteo
Carella, Angelo Michele
Chiappella, Annalisa
Volpetti, Stefano
Zinzani, Pier Luigi
D'Arco, Alfonso Maria
Evangelista, Andrea
Tucci, Alessandra
Piccaluga, Pier Paolo
Pileri, Stefano A.
Fanin, Renato
Levis, Alessandro
BLOOD, 2013, 122 (21)
[2] Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Islam, Prioty
Rizzieri, David
Lin, Chenyu
de Castro, Carlos
Diehl, Louis
Li, Zhiguo
Moore, Joseph
Morris, Tod
Beaven, Anne
CANCER INVESTIGATION, 2021, 39 (10) : 871 - 879
[3] Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Zaja, Francesco
Volpetti, Stefano
Chiappella, Annalisa
Salvi, Flavia
Carella, Angelo M.
Ibatici, Adalberto
Piccaluga, Pier Paolo
Pileri, Stefano A.
Rossi, Davide
Zinzani, Pier Luigi
Patti, Caterina
Vitolo, Umberto
D'Arco, Alfonso
Tucci, Alessandra
Franceschetti, Silvia
Evangelista, Andrea
Lenti, Valentina
Fanin, Renato
Levis, Alessandro
BLOOD, 2014, 124 (21)
[4] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Lenz, Georg
Hawkes, Eliza
Verhoef, Gregor
Haioun, Corinne
Thye, Lim Soon
Heo, Dae Seog
Ardeshna, Kirit
Chong, Geoffrey
Christensen, Jacob Haaber
Shi, Vivian
Lippert, Susanne
Niemeyer, Florian
Piraino, Paolo
Pena, Carol Elaine
Buvaylo, Viktoriya
Childs, Barrett H.
Gorbatchevsky, Igor
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
Merli, Francesco
Cavallo, Federica
Salvi, Flavia
Tucci, Alessandra
Musuraca, Gerardo
Nassi, Luca
Merli, Michele
Tani, Monica
Gini, Guido
Ferrari, Angela
Molinari, Anna Lia
Liberati, Anna Marina
Conconi, Annarita
Matteucci, Paola
Bari, Alessia
Scalone, Renato
Ferrero, Simone
Zanni, Manuela
Mammi, Caterina
Luminari, Stefano
JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (01) : 37 - 40
[6] Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi
Nassi, Luca
De Sanctis, Vitaliana
Loseto, Giacomo
Gerardi, Chiara
Allocati, Eleonora
Ciavarella, Sabino
Minoia, Carla
Guarini, Attilio
Bari, Alessia
CANCERS, 2022, 14 (03)
[7] Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
Assouline, Sarit E.
Nielsen, Torsten Holm
Yu, Stephen
Alcaide, Miguel
Chong, Lauren
MacDonald, David
Tosikyan, Axel
Kukreti, Vishal
Kezouh, Abbas
Petrogiannis-Haliotis, Tina
Albuquerque, Marco
Fornika, Daniel
Alamouti, Sepideh
Froment, Remi
Greenwood, Celia M. T.
Oros, Kathleen Klein
Camglioglu, Errol
Sharma, Ayushi
Christodoulopoulos, Rosa
Rousseau, Caroline
Johnson, Nathalie
Crump, Michael
Morin, Ryan D.
Mann, Koren K.
BLOOD, 2016, 128 (02) : 185 - 194
[8] OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A MULTICENTRE PHASE 2 STUDY BY THE FONDAZIONE ITALIANA LINFOMI
Merli, F.
Luminari, S.
Salvi, F.
Cavallo, F.
Gini, G.
Musuraca, G.
Gaidano, G.
Cellini, C.
Merli, M.
Ferrari, A.
Molinari, A.
Liberati, A. M.
Conconi, A.
Matteucci, P.
Pozzi, S.
Musso, M.
Mammi, C.
Monaco, F.
Ferrero, S.
Tucci, A.
HAEMATOLOGICA, 2017, 102 : 17 - 17
[9] Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi
Merli, Francesco
Luminari, Stefano
Rossi, Giuseppe
Mammi, Caterina
Marcheselli, Luigi
Ferrari, Angela
Spina, Michele
Tucci, Alessandra
Stelitano, Caterina
Capodanno, Isabella
Fragasso, Alberto
Baldini, Luca
Bottelli, Chiara
Montechiarello, Elisa
Fogazzi, Stefano
Lamorgese, Cinzia
Cavalli, Lara
Federico, Massimo
LEUKEMIA & LYMPHOMA, 2014, 55 (01) : 38 - 43
[10] Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi
Merli, Michele
Visco, Carlo
Spina, Michele
Luminari, Stefano
Ferretti, Virginia Valeria
Gotti, Manuel
Rattotti, Sara
Fiaccadori, Valeria
Rusconi, Chiara
Targhetta, Clara
Stelitano, Caterina
Levis, Alessandro
Ambrosetti, Achille
Rossi, Davide
Rigacci, Luigi
D'Arco, Alfonso Maria
Musto, Pellegrino
Chiappella, Annalisa
Baldini, Luca
Bonfichi, Maurizio
Arcaini, Luca
HAEMATOLOGICA, 2014, 99 (03) : 489 - 496

← 1 2 3 4 5 →